Pharmafile Logo
Pharmafocus logo
Advanced Search

Neupogen

Showing 8 posts of 8 posts found.

fda2outsideweb

FDA approves Pfizer biosimilar version of Amgen’s Neupogen

July 23, 2018
Sales and Marketing Amgen, FDA, Neupogen, Nivestym, Pfizer, pharma

The FDA has announced its decision to approve Pfizer’s Nivestym, the firm’s biosimilar version of Amgen’s Neupogen (filgrastim), for use …

News
zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

News

Amgen and Novartis tussle over biosimilar injunction

June 4, 2015
Sales and Marketing Amgen, FDA, Neupogen, Novartis

Novartis has begun its court battle with Amgen over its biosimilar of cancer drug Neupogen, which Amgen is trying to …

News

US Court blocks Novartis biosimilar Neupogen

May 8, 2015
Sales and Marketing Neupogen, Novartis, Zarxio, biosimilar, filagrastim, filgrastim-sndz

Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …

News

Novartis and Abbott start year with strong Q1 sales

April 23, 2015
Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials

Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …

News
Novartis image

Novartis secures first US biosimilar product

March 6, 2015
Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …

News
Sandoz image

Novartis biosimilar rivals Amgen offering

December 9, 2014
Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, filgrastim, zarzio

An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …

News

Novartis starts late-stage biosimilar trials for Amgen drugs

January 19, 2012
Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis

Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023